TrialSite News continues to develop a global network of individuals, from all walks of life, participating and sharing their experiences from around the world. They share a common bond: a dedication to health, community well-being and research, from randomized controlled trials to real world observations, contributing important observations related to COVID-19. Alan Cannell is one of these individuals. Originally from the UK, but based in the southern part of Brazil for many years, Mr. Cannell, an engineer by training who has participated in major projects around the world, shares his research observations as to the use of Ivermectin in Brazil. As TrialSite recently discussed, some municipal health departments in Brazil have approved Ivermectin-based regimens targeting COVID-19. This is a similar pattern to observations in some other parts of South America.
We were caught by the COVID outbreak in Paris. Despite the rumors coming out of Italy, the situation in France didn’t look so bad and, on Friday March 9, the bars and restaurants were full. On Monday, the city went into full lockdown. After three weeks and a series of cancelled flight...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).